Peer-Reviewed Publications

      A modelling approach to develop machine smoking protocols reflecting human puffing behaviour for conventional cigarettes

      Urban, H. J.; Gomm, W.; Schorp, M.
      Published
      Apr 1, 2008
      DOI
      10.2478/cttr-2013-0844
      Link to publication
      Topic
      Summary

      Our objective was to develop machine-smoking protocols (i.e. puff volume, puff duration and puff frequency) reflecting the distribution of human smoking behaviour as a complement to the International Standard (ISO) protocol. For this purpose, a modelling approach based on smoking topography and excretion data of urinary nicotine metabolites from clinical studies in the UK and Japan was used. Three smoking protocols (LOW, MEDIUM and HIGH) were based on the 10th percentile, the mean and the 90th percentile of the puff volumes obtained from topography data. The corresponding puff durations were estimated by linear regression analysis of the puff duration/puff volume relationship. Finally, puff frequency was estimated using a predictive model assuming that the nicotine yield is a linear function (i.e. proportional) to the amount of air actually drawn through the burning part of the cigarette. This approach was termed "nicotine proportion method" where the puff frequency is changed iteratively until it equals the corresponding nicotine uptake measured in human smokers during a clinical study. The assumption was verified by measuring the nicotine yield in the laboratory on three modelled protocols for four conventional cigarettes. In 10 out of 12 cases, a very good agreement was observed between the estimated nicotine yields obtained with our modelling approach and the measured nicotine yields obtained from smoking machines in the laboratory. Although smoking virtually identical cigarettes, smoking protocols based on topography and excretion data of urinary nicotine metabolites from the UK clinical study were different than those based on data from the study performed in Japan. This may be explained by different smoking behaviour between these two populations of smokers.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.